CD40 and melanoma: We previously reported that agonistic CD40 antibody therapy induced IL-1α in the melanoma microenvironment, which conferred adaptive resistance to agonistic CD40 antibody therapy through polymorphonuclear MDSCs (PMN-MDSCs)28.